Press release |

Brazilian court suspends Gilead's patent on hepatitis C medicine sofosbuvir

Photograph by Peter Bauza
MSF and other civil society protests in Munich at the European Patent Office against Gilead's monopoly on sofosbuvir, Germany 2018.

Intellectual property issues cannot be disconnected from their impact on public health and people´s lives.

Ana de Lemos
Executive Director
MSF-Brazil

Background:

25 September 2018 – A Brazilian Federal Court has suspended a patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C drug sofosbuvir. The decision was announced on Monday, September 24th.

The patent had been granted to Gilead the week before by Instituto Nacional da Propriedade Industrial (INPI), the Brazilian patent office. However, given the impact this granted patent would have on public health and on the government’s budget, the court has suspended the patent and ordered the patent office to review its ruling, opening up the possibility for companies in Brazil to produce affordable generic versions of sofosbuvir. Key patents on sofosbuvir have already been rejected in China, Egypt and Ukraine, and decisions are pending or being appealed in several other countries including Argentina, India, Thailand and Russia.

Sofosbuvir is an oral, direct-acting antiviral drug that is safer, more tolerable and more effective than older hepatitis C treatments. Sofosbuvir forms the backbone of most hepatitis C treatment combinations, but sofosbuvir and its key companion drugs are priced out of reach for people who need them in many countries, including Brazil. About 700,000 Brazilians have the disease but no access to treatment due to its high price.

The Brazilian government has set the goal of eliminating hepatitis C by 2030, but with treatment at current prices, it's very likely that budget constraints will limit the scope of national treatment plans. Therefore, it's essential that competition among generic manufacturers is allowed, in order to lower prices and save more lives.


Statement from Ana de Lemos, executive director, MSF-Brazil

“The Brazilian court's decision to suspend the patent for sofosbuvir is extremely encouraging, because it shows that intellectual property issues cannot be disconnected from their impact on public health and people's lives. MSF will continue to put pressure on local authorities to make sure the decision is not reversed. The 700,000 people in Brazil who still don't have access to the hepatitis C cure they need should not be let down. We have worked in coordination with other organizations to mobilize public opinion and were able to gather massive support behind this cause, putting the issue of access to affordable medicines on the public agenda and paving the way for the court's ruling.’’